Die Rolle der lokalen Therapie des Primärtumors bei der Behandlung des oligometastasierten Prostatakarzinoms

Zusammenfassung

Die bisherige Studienlage lässt es nicht zu, eine generelle Empfehlung zur lokalen Therapie bei oligometastasierten Prostatakarzinompatienten auszusprechen. Die Datenlage vornehmlich klinischer retrospektiver Studien deutet darauf hin, dass bezüglich des karzinomspezifischen – wie auch des Gesamtüberlebens einzelne Patienten profitieren können. Die zytoreduktive Prostatektomie ist an erfahrenen Zentren mit vergleichbarer Komplikationsrate zur Standardindikation durchführbar. Einzelne Patienten können von der Vermeidung von lokoregionären Sekundärkomplikationen profitieren. Multizentrische prospektive Studien laufen, die Ergebnisse sind noch ausstehend.

• Literatur

• 1 Robert Koch-Institut. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/kid_2017_c61_prostata.pdf?__blob=publicationFile
• 2 Leyh-Bannurah SR, Karakiewicz PI, Pompe RS. et al. Inverse stage migration paterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World J Urol. 2018 doi:10.1007/s00345–018–2396–2. [Epub ahead print]
• 3 Koo KC, Dasgupta P. Treatment of oligometastatic hormone-sensetive prostate cancer: a comprehensive review. Yonsei Med J 2018; 59: 567-579
• 4 Kim J, Park JS, Ham WS. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol 2017; 58: 307-316
• 5 Hellmann S, Weichselbaum RR. Oligometastasis. J Clin Oncol 1995; 13: 8-10
• 6 Chaloupka M, Herlemann A, Spek A. et al. Cytoreductive, radical prostatectomy in metastatic prostate cancer. Urologe 2017; 56: 1430-1434
• 7 Engel J, Bastian PJ, Baur H. et al. Survival benefit of radical prostatectomy in lymph node-positve patients with prostate cancer. Eur Urol 2010; 57: 754-761
• 8 Steuber T, Budaus L, Walz J. et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive cancer in the prostate specific antigen era: a confirmatory study. BJU Int 2011; 107: 1755-1761
• 9 Moschini M, Sharma V, Zattoni F. et al. Risk stratification of pN+ prostate cancer after radical prostatectomy from a large single institutional series with longterm followup. J Urol 2016; 195: 1773-1778
• 10 Rusthoven CG, Carlson JA, Waxweiler TV. et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 2014; 88: 1064-1073
• 11 Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65: 1058-1066
• 12 Leyh-Bannurah SR, Gazdovich S, Budaus L. et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol 2017; 72: 118-124
• 13 Pompe RS, Tilki D, Preisser F. et al. Survival benefit of local versus no local treatment for metastatic prostate cancer – impact of baseline PSA and metastatic substages. Prostate 2018; 78: 753-757
• 14 Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasability and case-control study. J Urol 2015; 193: 832-838
• 15 Cho Y, Chang JS, Rha KH. et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?. PloS ONE 2016; 11: e0147191
• 16 Steuber T, Berg KD, Roder MA. et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 2017; 3: 646-649
• 17 Rexer H. (2015) Metastatic, hormone-naive prostate cancer interventional study: Multicenter, prospective, randomized study to evaluate the effect of standard drug therapy with or without radical prostatectomy in patients with limited bone metastasized prostate cancer (G-RAMPP – the AUO AP 75/13 study). Urologe A 2015; 54: 1613-1616